FDA approves UCB's ZILBRYSQ autoinjector for at-home self-administration in myasthenia gravis

The US FDA has approved UCB's ZILBRYSQ autoinjector for at-home self-administration in adults with generalized myasthenia gravis who test positive for the anti-acetylcholine receptor antibody. This device offers a convenient, once-daily, self-injection alternative to infusion or syringe administration, supported by clinical studies demonstrating effective drug delivery.

This Wire brief sits within Fusion42's coverage of Biotech.